ORSERDU™ may cause lipid abnormalities, fetal harm, and should be avoided in patients with severe hepatic impairment.  

Precautions for Using ORSERDU™

Before starting ORSERDU™, patients should be screened for lipid abnormalities, as the drug may cause increased cholesterol and triglyceride levels. Regular monitoring of lipid profiles is recommended during treatment. Additionally, ORSERDU™ is contraindicated in pregnant women due to the potential for embryo-fetal toxicity. Effective contraception is advised during treatment. Severe hepatic impairment (Child-Pugh C) is a contraindication for using ORSERDU™, while for moderate hepatic impairment (Child-Pugh B), a dosage reduction is necessary. Concomitant use with strong or moderate CYP3A4 inducers and inhibitors should be avoided due to possible drug interactions.